Introduction {#Sec1}
============

Postmenopausal osteoporosis (PMOP) is a common metabolic bone disorder characterized by low bone mineral density (BMD) and increased fracture risks in postmenopausal women^[@CR1],[@CR2]^. The pathogenesis of PMOP remains unclear^[@CR3]^. In recent years, the association between genetic factors and PMOP susceptibility has been highlighted^[@CR4]--[@CR7]^.

Vitamin D has a wide range of biological functions, including calcium and phosphate homeostasis, skeletal metabolism and vascular function^[@CR8]^. Vitamin D receptor (VDR) is the target receptor to regulate the transcription of Vitamin D, and is also thought to play a key role in cellular differentiation and proliferation^[@CR9]^. Recently, VDR gene polymorphisms like VDR *Apa*I, VDR *Bsm*I, VDR *Cdx*2, VDR *Fok*I and VDR *Taq*I are getting an increasing recognition of importance as more studies have verified their significant associations with several diseases^[@CR9],[@CR10]^.

More attention has been paid to the relationship between VDR gene polymorphisms and PMOP risk and BMD in postmenopausal women. Nevertheless, there are sdiscrepancies over this issue^[@CR11]--[@CR14]^. Although previous meta-analyses reported associations between VDR polymorphisms and osteoporosis risk, the results are conflicting^[@CR9],[@CR15],[@CR16]^. To the best of our knowledge, there lacks evidence to confirm the relationship between VDR *Apa*I, VDR *Bsm*I, VDR *Cdx*2, VDR *Fok*I and VDR *Taq*I polymorphisms and osteoporosis risk in postmenopausal women. In addition, the relationship between VDR gene polymorphisms and BMD in postmenopausal women has also been widely studied, but the results are also controversial^[@CR11],[@CR17]--[@CR26]^. The aim of the present meta-analysis is to determine whether there is any significant association between VDR gene polymorphisms (VDR *Apa*I, VDR *Bsm*I, VDR *Cdx*2, VDR *Fok*I and VDR *Taq*I) and susceptibility to osteoporosis and BMD in postmenopausal women.

Results {#Sec2}
=======

Characteristics of the eligible studies {#Sec3}
---------------------------------------

A total of 58 studies^[@CR11]--[@CR14],[@CR17]--[@CR25],[@CR27]--[@CR71]^ meeting the inclusion and exclusion criteria were recruited in our meta-analysis, among which 47 studies^[@CR11]--[@CR14],[@CR17]--[@CR20],[@CR22],[@CR23],[@CR25],[@CR27]--[@CR62]^ explored the relationships between VDR gene polymorphisms and PMOP susceptibility in postmenopausal women, and 26 studies^[@CR11],[@CR17],[@CR18],[@CR21]--[@CR24],[@CR26]--[@CR28],[@CR34],[@CR42],[@CR46],[@CR47],[@CR52],[@CR54],[@CR61],[@CR63]--[@CR71]^ eported the BMD value in PMOP women with various VDR genotypes. The study selection and inclusion processes are shown in Fig. [1](#Fig1){ref-type="fig"}. The general characteristics of the studies reporting the association with PMOP risk are indicated in Table [1](#Tab1){ref-type="table"}, and the characteristics of the studies measuring BMD in PMOP women carrying VDR *Apa*I, VDR *Bsm*I, VDR *Taq*I, VDR *Cdx*2 and VDR *Fok*I polymorphisms are shown in Table [2](#Tab2){ref-type="table"}.Figure 1The study selection and inclusion process.Table 1General characteristics of studies assciated with postmenopausal osteoporosis risk.AuthorYearEthnicitySample SizeVDR *Apa*ICaseControlCaseControlAaAAAaaaAaAAAaaaSassi *et al*.2015Caucasian1412311031792553631672952611590Castelán-Martínez *et al*.2015Caucasian38714733244286160141127167267546González-Mercado *et al*.2013Caucasian888799772647159975294117Marozik *et al*.2013Caucasian54777038232476292143429Yoldemir *et al*.2011Caucasian130130128132346036135125317326Luan *et al*.2011Asian7722793614292622123310217108Tanriover *et al*.2010Caucasian505053471523125743221315Seremak-Mrozikiewicz *et al*.2009Caucasian163631521743582465670123219Uysal *et al*.2008Caucasian10014612080355015171121467921Chen *et al*.2007Asian82113241404166265161124160Mitra *et al*.2006Asian119971449450442510193343330Duman *et al*.2004Caucasian7566826813566755715456Douroudis *et al*.2003Caucasian35443634111410602817261Zajícková *et al*.2002Caucasian6533795123339372910176Langdahl *et al*.2000Caucasian787488682244128266253217Gennari *et al*.1998Caucasian160144217103688111152136348426Vandevyver *et al*.1997Caucasian876998589204522769629197375127Riggs *et al*.1995Caucasian40128433712199135121385931**AuthorYearEthnicitySample SizeVDR** ***Bsm*** **ICaseControlCaseControlBbBBBbbbBbBBBbbb**D. Boroń *et al*.2015Caucasian2782923232331011215636921512811351Marozik *et al*.2013Caucasian5477555312311148106112640Pouresmaeili *et al*.2013Caucasian6482616714331759105133336González-Mercado *et al*.2013Caucasian888840136628544613043846Efesoy *et al*.2011Caucasian4030334752312253551510Yoldemir *et al*.2011Caucasian130130117143227335109151226543Tanriover *et al*.2010Caucasian50504951151916455519724Mansour *et al*.2010Caucasian50206931271584361217Musumeci *et al*.2009Caucasian100200114863054161332671510382Mencej-Bedrac *et al*.2009Caucasian240228164316271101031802764010088Seremak-Mrozikiewicz *et al*.2009Caucasian163631202062766704779102726Pérez *et al*.2008Caucasian646869591735127264203216Uysal *et al*.2008Caucasian10014684116184834126166247844Mitra *et al*.2006Asian119971489051462276118193840Duman *et al*.2004Caucasian7566906018543765617427Zhu *et al*.2004Asian4015838426268119197710546Douroudis *et al*.2003Caucasian3544185231220493910295Chen *et al*.2003Asian402177307333390318Lisker *et al*.2003Caucasian66574785151734645013386Borjas-Fajardo *et al*.2003Caucasian5455763228206585211368Zajícková *et al*.2002Caucasian653366642124203333101310Pollak *et al*.2001Asian75143648613382499187166760Aerssens *et al*.2000Caucasian1352391121582660492292495212562Langdahl *et al*.2000Caucasian808084762338198476253421Garrofé *et al*.2000Caucasian75516783949174260102219Poggi *et al*.1999Caucasian50225475363594753639567Go´mez *et al*.1999Caucasian3712234407201091153205151Gennari *et al*.1998Caucasian15513617213840922398174117649Zhang *et al*.1998Asian17162331031414310014148Vandevyver *et al*.1997Caucasian866987498125024622774127368203Houstan *et al*.1996Caucasian4444355381917375191916Berg *et al*.1996Caucasian19301622487273381111Yanagi *et al*.1996Asian46663656121222111212757Riggs *et al*.1995Caucasian40129384292011101157206148Lim *et al*.1995Asian7270131312961111291960Melhus *et al*.1994Caucasian707657831429271034934357**AuthorYearEthnicitySample SizeVDR** ***Taq*** **ICaseControlCaseControlTtTTTtttTtTTTttt**Ziablitsev *et al*.2015Caucasian4430583020186204041214Sassi *et al*.2015Caucasian1412311731095857263011611039533González-Mercado *et al*.2013Caucasian888813640542861284846366Marozik *et al*.2013Caucasian5477604817261110252392414Yoldemir *et al*.2011Caucasian13013016199515920157103495922Tanriover *et al*.2010Caucasian5050594115296673325178Seremak-Mrozikiewicz *et al*.2009Caucasian163632151117859267353222912Uysal *et al*.2008Caucasian10014612674404614183109547517Mitra *et al*.2006Asian1199711012834424311975443122Duman *et al*.2004Caucasian756688622342107458232815Douroudis *et al*.2003Caucasian354451191913343458279Zajícková *et al*.2002Caucasian65337753233111363011148Langdahl *et al*.2000Caucasian787587692341149060283413Masi *et al*.1998Caucasian90111621181336418214096438Gennari *et al*.1998Caucasian16014415316733874019593627111Vandevyver *et al*.1997Caucasian462845240113053412279115934Riggs *et al*.1995Caucasian4113045371123716397535720**AuthorYearEthnicitySample SizeVDR** ***Cdx*** **2CaseControlCaseControlGAGGGAAAGAGGGAAA**Marozik *et al*.2013Caucasian54779513411301302453240Ziablitsev *et al*.2015Caucasian4430523616208164421216Mencej-Bedrac *et al*.2009Caucasian2392283859315575939264172488**AuthorYearEthnicitySample SizeVDR** ***Fok*** **ICaseControlCaseControlFfFFFfffFfFFFfff**Langdahl *et al*.2000Caucasian798097612841109961343115Tanriover *et al*.2010Caucasian5050762427221762429183Zajícková *et al*.2002Caucasian6533805026281135317215Yasovanthi *et al*.2011Caucasian247254327167104119243681401221248Gennari *et al*.1999Caucasian16411919313560733116177535511Choi *et al*.2000Asian48654749122313854526336Lucotte G *et al*.1999Caucasian1241051598945691013278405213Lisker *et al*.2003Caucasian6557834727299694520298Mitra *et al*.2006Asian1199711812038423912569463318Mansour *et al*.2010Caucasian5020772334974002000Mencej-Bedrac *et al*.2009Caucasian24022828419688108443071491059726Pérez *et al*.2008Caucasian646876522232108056223610Yoldemir *et al*.2011Caucasian130130187736655917981625513Mohammadi *et al*.2015Caucasian1393116311580356253711317González-Mercado *et al*.2013Caucasian888898782548159383244519Table 2Characteristics of included studies of lumbar spine, femoral neck and Ward's triangle BMD in VDR *Apa*I, VDR *Bsm*I, VDR *Taq*I, VDR *Cdx*2 and VDR *Fok*I genotypes.VDR *Apa*ILumbar Spine BMDVDR *Apa*IFemoral Neck BMDAAAaaaAAAaaaAuthorYearEthnicityNMean ± SDNMean ± SDNMean ± SDAuthorYearEthnicityNMean ± SDNMean ± SDNMean ± SDPedrera-Canal *et al*.2015Caucasian850.74 ± 0.081250.74 ± 0.07640.75 ± 0.08Marozik *et al*.2013Caucasian230.77 ± 0.03240.87 ± 0.0370.86 ± 0.04Marozik *et al*.2013Caucasian230.91 ± 0.04240.98 ± 0.0371.04 ± 0.06Horst-Sikorska *et al*.2013Caucasian1070.69 ± 0.082950.69 ± 0.091350.75 ± 0.09Horst-Sikorska *et al*.2013Caucasian1070.85 ± 0.142950.84 ± 0.151350.85 ± 0.14Duman *et al*.2004Caucasian130.69 ± 0.02560.69 ± 0.01Yoldemir *et al*.2011Caucasian341.02 ± 0.11601.00 ± 0.12361.01 ± 0.12Pedrera-Canal *et al*.2015Caucasian850.69 ± 1.001250.72 ± 0.09640.71 ± 0.10Duman *et al*.2004Caucasian130.83 ± 0.05560.79 ± 0.02Yoldemir *et al*.2011Caucasian340.84 ± 0.08600.81 ± 0.09360.87 ± 0.14Vandevyver *et al*.1997Caucasian170.73 ± 0.08340.71 ± 0.13140.67 ± 0.09**VDR** ***Bsm*** **ILumbar Spine BMDVDR** ***Bsm*** **IFemoral Neck BMDBBBbbbBBBbbb**Marozik *et al*.2013Caucasian120.95 ± 0.06310.95 ± 0.03111.02 ± 0.04Marozik *et al*.2013Caucasian120.79 ± 0.03310.84 ± 0.03110.85 ± 0.03D. Boroń *et al*.2015Caucasian1010.8 ± 0.021210.83 ± 0.04560.83 ± 0.06Garrofé *et al*.2000Caucasian170.71 ± 0.10650.73 ± 0.08230.76 ± 0.07Garrofé *et al*.2000Caucasian170.79 ± 0.04650.79 ± 0.03230.8 ± 0.04Ge *et al*.2006Asian50.65 ± 0.02330.69 ± 0.071420.69 ± 0.08Poggi *et al*.1999Caucasian60.84 ± 0.14350.88 ± 0.1390.91 ± 0.16Garnero *et al*.2005Caucasian900.80 ± 0.11620.81 ± 0.12330.81 ± 0.12Ge *et al*.2006Asian50.76 ± 0.07330.73 ± 0.071420.74 ± 0.09Houstan *et al*.1996Caucasian80.79 ± 0.04190.73 ± 0.03170.67 ± 0.03Houstan *et al*.1996Caucasian80.87 ± 0.05190.89 ± 0.04170.81 ± 0.04Horst-Sikorska *et al*.2013Caucasian820.70 ± 0.092250.70 ± 0.091930.69 ± 0.08Horst-Sikorska *et al*.2013Caucasian820.86 ± 0.152250.85 ± 0.151930.84 ± 0.14Duman *et al*.2004Caucasian180.67 ± 0.02540.69 ± 0.01Palomba *et al*.2005Caucasian2080.62 ± 0.064160.61 ± 0.064760.62 ± 0.06Aerssens *et al*.2000Caucasian260.71 ± 0.09600.69 ± 0.10490.70 ± 0.09Duman *et al*.2004Caucasian180.84 ± 0.04540.79 ± 0.02Mencej-Bedrac *et al*.2009Caucasian270.60 ± 0.081100.64 ± 0.091030.62 ± 0.08Aerssens *et al*.2000Caucasian261.01 ± 0.22600.81 ± 0.16490.87 ± 0.21Pérez *et al*.2008Caucasian160.60 ± 0.01430.58 ± 0.01130.54 ± 0.04Palomba *et al*.2003Caucasian120.58 ± 0.08230.58 ± 0.08290.57 ± 0.07Yoldemir *et al*.2011Caucasian220.82 ± 0.06730.84 ± 0.11350.84 ± 0.11Vandevyver *et al*.1997Caucasian100.69 ± 0.08380.71 ± 0.12170.72 ± 0.11Wu *et al*.2007Asian120.70 ± 0.07600.71 ± 0.091260.69 ± 0.09Mencej-Bedrac *et al*.2009Caucasian270.73 ± 0.091100.75 ± 0.081030.74 ± 0.10Pedrera-Canal *et al*.2015Caucasian1070.69 ± 0.102150.71 ± 0.061340.7 ± 0.09Pérez *et al*.2008Caucasian170.69 ± 0.02340.66 ± 0.02130.67 ± 0.02Moran *et al*.2015Caucasian180.72 ± 0.10650.70 ± 0.10670.70 ± 0.09Yoldemir *et al*.2011Caucasian221.02 ± 0.08731.02 ± 0.12351.01 ± 0.13Creatsa *et al*.2011Caucasian70.77 ± 0.08230.73 ± 0.16120.66 ± 0.15Wu *et al*.2007Asian120.87 ± 0.09600.87 ± 0.121260.77 ± 0.11Pedrera-Canal *et al*.2015Caucasian1070.77 ± 0.072150.74 ± 0.071340.75 ± 0.07Moran *et al*.2015Caucasian180.71 ± 0.06650.72 ± 0.08670.74 ± 0.06Creatsa *et al*.2011Caucasian70.92 ± 0.14230.85 ± 0.18120.93 ± 0.17**VDR** ***Bsm*** **IWard's triangle BMDVDR** ***Taq*** **IFemoral Neck BMDBBBbbbTTTtttAuthorYearEthnicityNMean ± SDNMean ± SDNMean ± SD**Garrofé *et al*.2000Caucasian170.58 ± 0.11650.59 ± 0.09230.64 ± 0.11Ge *et al*.2006Asian50.50 ± 0.06330.49 ± 0.081420.49 ± 0.13Duman *et al*.2004Caucasian180.51 ± 0.03540.54 ± 0.02Wu *et al*.2007Asian120.66 ± 0.09600.58 ± 0.101260.57 ± 0.10**VDR** ***Taq*** **ILumbar Spine BMDVDR** ***Taq*** **IFemoral Neck BMDTTTtttTTTtt**Marozik *et al*.2013Caucasian171.01 ± 0.03260.95 ± 0.04110.91 ± 0.07Marozik *et al*.2013Caucasian170.85 ± 0.02260.84 ± 0.03110.77 ± 0.03Ziablitsev *et al*.2015Caucasian242.16 ± 0.09301.57 ± 0.01201.39 ± 0.18Horst-Sikorska *et al*.2013Caucasian1990.69 ± 0.082180.7 ± 0.09840.69 ± 0.09Horst-Sikorska *et al*.2013Caucasian1990.83 ± 0.142180.85 ± 0.15840.87 ± 0.15Duman *et al*.2004Caucasian230.73 ± 0.02420.68 ± 0.02100.63 ± 0.03Duman *et al*.2004Caucasian230.87 ± 0.03420.77 ± 0.02100.80 ± 0.05Yoldemir *et al*.2011Caucasian510.86 ± 0.13590.81 ± 0.08200.84 ± 0.08**VDR** ***Cdx*** **2Lumbar Spine BMDVDR** ***Cdx*** **2Femoral Neck BMDGGGAAAGGGAAA**Marozik *et al*.2013Caucasian410.96 ± 0.03130.99 ± 0.0400Marozik *et al*.2013Caucasian410.82 ± 0.02130.87 ± 0.0400Ziablitsev *et al*.2015Caucasian182.2 ± 0.14321.51 ± 0.17241.83 ± 0.18Zhang *et al*.2006Asian440.62 ± 0.02970.62 ± 0.01300.59 ± 0.02Zhang *et al*.2006Asian440.75 ± 0.03970.78 ± 0.01300.79 ± 0.024Mencej-Bedrac *et al*.2009Caucasian1550.62 ± 0.08750.62 ± 0.0990.69 ± 0.11Mencej-Bedrac *et al*.2009Caucasian1550.75 ± 0.09750.73 ± 0.0890.73 ± 0.07**VDR** ***Fok*** **ILumbar Spine BMDVDR** ***Fok*** **IFemoral Neck BMDFFFfffFFFfff**Yasovanthi *et al*.2011Caucasian1040.87 ± 0.121190.85 ± 0.15240.75 ± 0.17Lucotte G *et al*.1999Caucasian450.64 ± 0.12690.63 ± 0.12100.60 ± 0.08Lucotte G *et al*.1999Caucasian450.81 ± 0.15690.79 ± 0.14100.80 ± 0.15Mencej-Bedrac *et al*.2009Caucasian880.63 ± 0.081080.63 ± 0.09440.62 ± 0.08Mencej-Bedrac *et al*.2009Caucasian880.74 ± 0.091080.75 ± 0.08440.74 ± 0.10Pérez *et al*.2008Caucasian190.59 ± 0.01330.58 ± 0.01100.55 ± 0.02Pérez *et al*.2008Caucasian210.70 ± 0.02330.66 ± 0.0190.64 ± 0.03Yoldemir *et al*.2011Caucasian550.85 ± 0.11550.83 ± 0.1090.86 ± 0.06Yoldemir *et al*.2011Caucasian661.00 ± 0.12551.03 ± 0.1291.10 ± 0.09Xing *et al*.2010Asian280.86 ± 0.09540.85 ± 0.10210.84 ± 0.12

Power analysis {#Sec4}
--------------

Before this meta-analysis, a power analysis was conducted by using the Power and Precision V4 software to verify whether the included studies could offer adequate power (\>80%). The statistical power in our study was sufficient to detect the associations between VDR gene polymorphisms and PMOP risk.

VDR polymorphisms and PMOP risk {#Sec5}
-------------------------------

### VDR *Apa*I {#Sec6}

Overall, our study showed a significant association between VDR *Apa*I polymorphism and PMOP risk. When stratified by ethnicity, subgroup analysis indicated that there was also a significant association between VDR *Apa*I polymorphism and PMOP risk in Caucasian populations, while there lacked a significant association in Asian populations. All the data are shown in Table [3](#Tab3){ref-type="table"}, and Fig. [2](#Fig2){ref-type="fig"}.Table 3Results of genetic models for VDR *Apa*I, VDR *Bsm*I, VDR *Taq*I, VDR *Cdx*2 and VDR *Fok*I polymorphisms and osteoporosis susceptibility in postmenopausal women.ComparisonNTest of associationModelTest of heterogeneityBegg's testEgger's testOR95% CI*P* value*P* valueI^2^ (%)*P* value*P* value**VDR** ***Apa*** **I** Overall18 a *vs*. A0.950.793--1.130.53R\<0.00169.20.6490.575 aa *vs*. AA0.840.61--1.150.271R\<0.00160.40.3250.405 Aa *vs*. AA0.860.73--1.010.063F0.09132.40.130.075 Aa/aa *vs*. AA**0.840.73--0.980.022**F0.02045.30.0580.076 aa *vs*. AA/Aa0.930.70--1.230.609R\<0.00166.60.3630.484Caucasian15 a *vs*. A0.940.80--1.120.505R0.00161.6 aa *vs*. AA0.840.58--1.200.33R0.00160.5 Aa *vs*. AA**0.840.70--0.990.042**F0.04641.7 Aa/aa *vs*. AA**0.850.72--1.000.047**F0.01748.8 aa *vs*. AA/Aa0.930.69--1.240.609R0.00258.5 Asian3 a *vs*. A0.990.48--2.060.98R\<0.00169.2 aa *vs*. AA0.860.38--1.960.727R0.03370.8 Aa *vs*. AA1.040.65--1.670.879F0.8030 Aa/aa *vs*. AA0.810.57--1.150.238F0.16344.8 aa *vs*. AA/Aa0.960.36--2.600.942R\<0.00188.1**VDR** ***Bsm*** **I** Overall36 B *vs*. b1.211.00--1.460.052R\<0.001830.2150.198 BB *vs*. bb1.40.97--2.010.072R\<0.00179.40.3580.194 Bb *vs*. bb1.270.99--1.640.06R\<0.00173.40.5050.409 BB/Bb *vs*. bb**1.321.01--1.720.044**R\<0.00179.50.5220.314 BB *vs*. Bb/bb1.210.93--1.570.159R\<0.00171.90.2020.107Caucasian29 B *vs*. b1.090.90--1.330.385R\<0.00182.4 BB *vs*. b1.180.81--1.710.396R\<0.00178.3 Bb *vs*. bb1.190.89--1.590.246R\<0.00176.8 BB/Bb *vs*. bb1.190.88--1.590.262R\<0.00180.6 BB *vs*. Bb/bb1.080.81--1.370.682R\<0.00168.9 Asian7 B *vs*. b**2.021.30--3.120.002**R0.00568.1 BB *vs*. bb**4.162.20--7.88**\<**0.001**R0.20732.1 Bb *vs*. bb**1.731.24--2.420.001**R0.4550 BB/Bb *vs*. bb**2.141.34--3.420.001**R0.06449.6 BB *vs*. Bb/bb**2.981.76--5.05**\<**0.001**R0.26723.1**VDR** ***Taq*** **I** Overall17 t *vs*. T1.030.83--1.280.782R\<0.00175.60.1490.053 tt *vs*. TT1.030.68--1.560.873R\<0.00169.20.0530.023 Tt *vs*. TT1.090.81--1.470.573R\<0.00166.70.4840.363 Tt/tt *vs*. TT1.070.79--1.460.66R\<0.001730.2320.155 tt *vs*. Tt/TT1.030.76--1.390.848R0.00355.90.070.07 Caucasian16 t *vs*. T0.990.79--1.240.944R\<0.00174.4 tt *vs*. TT0.970.63--1.480.872R\<0.00167.9 Tt *vs*. TT1.050.77--1.440.747R\<0.00167.5 Tt/tt *vs*. T1.020.74--1.410.89R\<0.00172.7 tt *vs*. Tt/TT0.980.71--1.340.888R0.00554.7**VDR** ***Cdx*** **2** Caucasian3 A *vs*. G0.670.23--1.960.466R\<0.00190.910.322 AA *vs*. GG0.450.05--3.810.462R0.00978.710.74 GA *vs*. GG0.80.29--2.220.665R0.01177.80.2960.115 AA/GA *vs*. GG0.650.20--2.120.479R0.00284.10.2960.01 AA *vs*. GG/GA0.560.14--2.200.405R0.04966.810.866**VDR** ***Fok*** **I** Overall15 f *vs*. F1.10.91--1.330.301R\<0.00163.30.6210.615 ff *vs*. FF1.260.84--1.890.262R0.00161.410.451 Ff *vs*. FF1.140.97--1.330.113F0.18624.30.6210.402 Ff/ff *vs*. FF**1.191.03--1.380.021**F0.02945.30.3730.593 ff *vs*. Ff/FF1.230.87--1.750.243R0.00456.210.593 Caucasian13 f *vs*. F1.020.85--1.230.844R0.00657 ff *vs*. FF1.070.71--1.630.741R0.00656.4 Ff *vs*. FF1.10.93--1.300.26F0.15229.1 Ff/ff *vs*. FF1.120.96--1.310.146F0.0641.2 ff *vs*. Ff/FF1.080.75--1.560.684R0.01651.7 Asian2 f *vs*. F**1.881.38--2.58**\<**0.001**R0.8440 ff *vs*. FF**3.051.67--5.60**\<**0.001**R0.4080 Ff *vs*. FF1.530.92--2.540.101F0.9710 Ff/ff *vs*. FF**1.951.23--3.080.004**F0.9380 ff *vs*. Ff/FF**2.471.43--4.270.001**R0.3950*R*: random effect model.*F*: fixed effect model.Figure 2Forest plot describing the meta-analysis under the dominant model for the association between VDR *Apa*I polymorphism and the risk of PMOP (Aa/aa *vs*. AA).

### VDR *Bsm*I {#Sec7}

VDR *Bsm*I polymorphism was found to be significantly associated with risk of developing PMOP in the overall populations and Asian populations (Table [3](#Tab3){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). In contrast, we failed to observe any significant association between them in Caucasian populations (all *P* \> 0.05).Figure 3Forest plot describing the meta-analysis under the dominant model for the association between VDR *Bsm*I polymorphism and the risk of PMOP (BB/Bb vs. bb).

### VDR Cdx2 {#Sec8}

We failed to find any significant association between VDR *Cdx*2 polymorphism and PMOP risk in Caucasian populations (*P* \> 0.05), nor could we confirm the association in overall and Asian populations as there lacked relevant studies. The data are shown in Table [3](#Tab3){ref-type="table"}.

### VDR *Fok*I {#Sec9}

The random-effects OR estimated for PMOP susceptibility was 1.19 in the overall PMOP populations with VDR *Fok*I polymorphism (Table [3](#Tab3){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"}). A significant association was also observed between VDR *Fok*I polymorphism and PMOP risk in Asian populations, while no significant relationship was observed in Caucasian populations (all *P* \> 0.05) (Table [3](#Tab3){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"}).Figure 4Forest plot describing the meta-analysis under the dominant model for the association between VDR *Fok*I polymorphism and the risk of PMOP (Ff/ff vs. FF).

### VDR *Taq*I {#Sec10}

Regarding VDR *Taq*I polymorphism, no significant relationship was observed between VDR *Taq*I polymorphism and PMOP susceptibility in the overall populations and Caucasian populations (both *P* \> 0.05) (Table [3](#Tab3){ref-type="table"}). However, we did not perform the subgroup analysis to detect the association between VDR *Taq*I and PMOP in Asian populations as only one study was been searched out and no sufficient dat could be used to draw any firm conclusions in Asians.

VDR polymorphisms and BMD {#Sec11}
-------------------------

### VDR *Apa*I {#Sec12}

aa genotype of VDR *Apa*I was significantly associated with increased BMD in the femoral neck; while no significant difference of BMD was observed at lumbar spine between PMOP women carrying aa genotype and AA genotype (Table [4](#Tab4){ref-type="table"}). However, no significant difference was observed in either lumbar spine or femoral neck BMD between Caucasian PMOP women carrying Aa genotype and those carrying AA genotype (Table [4](#Tab4){ref-type="table"}).Table 4Meta-analysis of differences of Lumbar, Femoral Neck and Ward's triangle BMD between each genotype of VDR *Apa*I, *Bsm*I, *Taq*I, *Cdx*2 and *Fok*I polymorphism.VDR *Apa*IAa *vs*. AAaa *vs*. AATest of differencesModelTest of heterogeneityTest of differencesModelTest of heterogeneityNWMD (95% CI)*P* value*P* valueI^2^ (%)NWMD (95% CI)*P* value*P* valueI^2^ (%)Lumbar BMD (Caucasian)6−0.00 (−0.04, 0.04)0.896R\<0.00190.550.01 (−0.04, 0.07)0.571R\<0.00187.1Femoral Neck BMD (Caucasian)50.02 (−0.03, 0.07)0.488R\<0.00196.54**0.06 (0.05, 0.08)\<0.001**F0.15642.5VDR *Bsm*IBb *vs*. bbBB *vs*. bb**Lumbar BMD**Overall180.00 (−0.01, 0.02)0.699R\<0.00182.9180.01 (−0.01, 0.02)0.467R\<0.00178Caucasian16−0.00 (−0.02, 0.01)0.684R\<0.00178.516−0.00 (−0.02, 0.02)0.988R\<0.00176Asian20.05 (−0.05, 0.14)0.344R\<0.00194.420.07 (−0.01, 0.14)0.078R0.06870**Femoral Neck BMD**Overall140.01 (−0.00, 0.03)0.061R\<0.00170.2150.01 (−0.02, 0.03)0.618R\<0.00189.5Caucasian120.01 (−0.00, 0.03)0.087R\<0.00173.9130.01 (−0.02, 0.04)0.484R\<0.00190.1Asian20.01 (−0.01, 0.03)0.43R0.45602−0.02 (−0.05, 0.02)0.302R0.1454**Ward's triangle BMD**Overall3−0.01 (−0.04, 0.03)0.645R0.09557.630.02 (−0.07, 0.10)0.675R0.00283.7Asian20.01 (−0.02, 0.03)0.55R0.444020.05 (−0.02, 0.13)0.156R0.051−73.7VDR *Taq*ITt *vs*. TTtt *vs*. TTLumbar BMD (Caucasian)6−0.12 (−0.26, 0.03)0.108R\<0.00199.46−0.15 (−0.30, 0.01)0.06R\<0.00198.3Femoral Neck BMD (Caucasian)4−0.02 (−0.06, 0.01)0.186R\<0.00193.74−0.05 (−0.10, 0.00)0.072R\<0.00194.4VDR *Cdx*2GA *vs*. GGAA *vs*. GG**Lumbar BMD**Overall4−**0.15** (−**0.25**, −**0.04)0.007**R\<0.00198.93−0.11 (−0.26, 0.05)0.176R\<0.00197.2Caucasian3−**0.22** (−**0.43**, −**0.01)0.037**R\<0.00199.22−0.19 (−0.54, 0.15)0.274R\<0.00197.5**Femoral Neck BMD**Overall30.02 (−0.01, 0.04)0.229R0.00284.220.01 (−0.08, 0.11)0.776R0.0184.9Caucasian20.02 (−0.02, 0.07)0.254R0.01184.5VDR *Fok*IFf *vs*. FFff *vs*. FF**Lumbar BMD**Overall6−0.01 (−0.03, 0.01)0.342R0.00371.96−0.02 (−0.07, 0.03)0.481R\<0.00184.9Caucasian5−0.01 (−0.04, 0.02)0.444R0.00177.25−0.02 (−0.08, 0.04)0.584R\<0.00187.9Femoral Neck BMD (Caucasian)4−**0.02** (−**0.02**, −**0.01)\<0.001**F0.62604−0.02 (−0.05, 0.01)0.149R0.01671.1*R*: random effect model.*F*: fixed effect model.

### VDR *Bsm*I {#Sec13}

No significant difference of Ward's triangle BMD was observed between the Bb genotype and bb genotype in Asian and overall populations (both *P* \> 0.05) (Table [4](#Tab4){ref-type="table"}). In addition, we failed to observe any significant difference in lumbar spine BMD and femoral neck BMD between Bb and bb genotypes in either overall, Caucasian or Asian PMOP populations (all *P* \> 0.05). As shown in Table [4](#Tab4){ref-type="table"}, there was no significant difference in lumbar spine BMD, femoral neck BMD and Ward's triangle BMD between Caucasian and Asian PMOP women with BB genotype and those with bb genotype (all *P* \> 0.05).

### VDR Cdx2 {#Sec14}

Among PMOP women with VDR *Cdx*2 polymorphism, the GA genotype was significantly associated with reduced lumbar spine BMD in overall and Caucasian populations, but no significant difference was observed in the femoral neck (all *P* \> 0.05). In addition, VDR *Cdx*2 was also not significantly associated with BMD in lumbar spine and BMD in femoral neck in etither overall populations. All the data are shown in Table [4](#Tab4){ref-type="table"}.

### VDR *Fok*I {#Sec15}

The femoral neck BMD in Caucasian PMOP women with VDR *Fok*I Ff genotype was significantly lower than that in women with VDR *Fok*I FF genotype, while no significant difference was observed in lumbar spine BMD in either overall and Caucasian populations (Table [4](#Tab4){ref-type="table"}). The VDR *Fok*I ff genotype was not significantly associated with BMD of the lumbar spine and femoral neck in PMOP women (all *P* \> 0.05).

### VDR *Taq*I {#Sec16}

No significant difference was observed in lumbar spine BMD and femoral neck BMD between Caucasian PMOP women carrying VDR *Taq*I Tt, VDR *Taq*I tt and VDR *Taq*I TT genotypes (all *P* \> 0.05) (Table [4](#Tab4){ref-type="table"}).

Sensitivity analysis and publication bias {#Sec17}
-----------------------------------------

We performed a leave-one-out analysis, and any single study could be omitted, without any effect on the overall statistical significance, indicating that the results were stable. The Begg's and Egger's tests were performed and the results indicated that there was minimal evidence of publication bias. The shape of funnel plot was symmetrical, which also indicated that there was no publication bias in our study (Fig. [5](#Fig5){ref-type="fig"}).Figure 5Funnel plot of the VDR gene polymorphism and PMOP risk.

Discussion {#Sec18}
==========

VDR *Apa*I polymorphism and risk of PMOP and BMD {#Sec19}
------------------------------------------------

VDR *Apa*I polymorphism is located in the 3′-regulatory region of VDR gene (in intron 8), resulting in changes of biological functions of Vitamin D^[@CR31]^. Overall, VDR *Apa*I polymorphism has a protective effect against the development of PMOP in the overall populations and Caucasian populations, suggesting that postmenopausal women with VDR *Apa*I mutant might have less opportunity to suffer from PMOP compared with wide genotypes, which is consistent with many other studies^[@CR27],[@CR31],[@CR41]^. However, controversial results were reported in Douroudis's study^[@CR40]^. In addition, the meta-analysis by Zintzaras *et al*.^[@CR15]^ reported that the allele contrast for Caucasian populations showed no association for *Apa*I, which is inconsistent with our finding. When we compared our study with this study^[@CR15]^, we could find that several studies^[@CR12],[@CR27],[@CR31]--[@CR39]^ performed after the publication year of it^[@CR15]^ were searched out and included in our pooled analysis, suggesting that our meta-analysis could provide a more precise evaluation of the relationship between VDR *Apa*I polymorphism and PMOP risk.

In our study, we found that the aa genotype of VDR *Apa*I was significantly associated with increased BMD in the femoral neck, which is consistent with some studies^[@CR21],[@CR27]^. However, no significant difference in BMD was observed at the lumbar spine, which is consistent with three case-control studies^[@CR21],[@CR24],[@CR34]^. Marozik *et al*.^[@CR27]^ reported a significant association between VDR *Apa*I polymorphism and lumbar spine BMD in PMOP women, and in their opinion, VDR *Apa*I polymorphism might be a useful marker for osteoporosis screening at least in Belarusian women. VDR *Apa*I polymorphism is found in the non-coding region of the VDR gene and may have no significant effect on the final protein product; therefore, why there are controversial results in lumbar spine and femoral neck BMD needs to be further studied. In addition, no significant difference was observed in either lumbar spine or femoral neck BMD between Caucasian PMOP women carrying Aa genotype and those carrying AA genotype, suggesting that different genotypes might have different effects on BMD.

VDR *Bsm*I polymorphism and risk of PMOP and BMD {#Sec20}
------------------------------------------------

VDR *Bsm*I is located in the 3′ untranslated region, and involved in regulating the stability of VDR mRNA. Our study showed that VDR *Bsm*I was significantly associated with the increased risk of developing PMOP in the overall populations as well as Asian populations, which is consistent with three previous studies^[@CR39],[@CR48],[@CR56]^. In contrast, no association was observed in some other studies^[@CR49],[@CR51],[@CR53],[@CR57]^. The combination of different original data in each study might have great impact on the pooled distribution of each genotype, which might be an important contributor to the different results of our results and other studies. Our results are consistent with Jia *et al*.^[@CR16]^ and Zintzaras *et al*.'s study^[@CR15]^. However, no significant association was observed in Asian populations in other studies^[@CR8],[@CR9],[@CR16]^. As Qin *et al*.^[@CR9]^ included all the osteoporotic patients, and Zhao *et al*.^[@CR8]^ only analyzed three studies, our study may provide a more precise evaluation than theirs. As no significant association was observed between VDR *Bsm*I and PMOP risk in Caucasian populations, ethnicity might be a factor contributing to this difference with Asian populations.

We compared BMD at the lumbar spine, femoral neck or Ward's triangle in PMOP women with BB, Bb and bb genotypes, and found that PMOP women carrying Bb genotype or BB genotype were not at a significantly higher risk of low BMD at lumbar spine, femoral neck, and Ward's triangle than those carrying bb genotype. As VDR *Bsm*I may not affect the amino acid sequence of VDR, it is easily understood that *Bsm*I Bb and BB genotype might not play a key role in BMD at lumbar spine, femoral neck, and Ward's triangle. Two studies^[@CR72],[@CR73]^ found no relationship between VDR *Bsm*I polymorphism and fracture risk in PMOP women, which verifies our results on the other hand.

Interestingly, our results showed consistency: VDR *Apa*I was associated with a decreased risk of PMOP, and high levels of BMD, whereas *Bsm*I was associated with an increased risk of PMOP and did not play a key role in BMD. Theoretically, the consistent results should be observed in the subgroup analysis, for both VDR *Apa*I and VDR *Bsm*I have influences on the stability of VDR mRNA. However, different gene locations of VDR *Apa*I and VDR *Bsm*I may lead to different biological functions. Thus, the different role of VDR *Apa*I and VDR *Bsm*I in the etiology and pathogenesis of PMOP and BMD may be an important contributor to the controversial findings in our study. However, the exact mechanism of the VDR *Apa*I and VDR *Bsm*I polymorphism requires further investigation.

VDR *Cdx*2 polymorphism and risk of PMOP and BMD {#Sec21}
------------------------------------------------

VDR *Cdx*2 polymorphism is located in the promoter region of VDR gene, which is considered to be associated with the level of calcium absorption and the receptor's activation to Vitamin D. It was found that VDR *Cdx*2 was not significantly associated with PMOP risk in Caucasian populations, which is consistent with the finding of Marozik *et al*.^[@CR27]^. One previous study^[@CR28]^ showed that VDR *Cdx*2 played a protective role against the risk of PMOP, which is inconsistent with the result reported by Mencej-Bedrac *et al*.^[@CR46]^, while 74 postmenopausal women were examined in the study of Ziablitsev *et al*.^[@CR28]^, which might contribute to this difference.

We found that GA genotype of VDR *Cdx*2 had an increased risk of developing low BMD at the lumbar spine in overall and Caucasian populations compared with GG genotype. In addition, no significant association was observed at femoral neck BMD, which is consistent with Marozik *et al*.'s study^[@CR27]^ and inconsistent with other two studies^[@CR28],[@CR46]^. As to the AA genotype of VDR *Cdx*2, no significant difference in lumar BMD or femoral neck BMD was observed between PMOP women with AA genotype and those with GG genotype in either overall or Caucasian populations. In Mencej-Bedrac *et al*.'s study^[@CR46]^, they observed an association between the *Cdx*2 polymorphism and vertebral fracture risk; therefore, large sample-size studies are required before a more convincing conclusion can be made.

VDR *Fok*I polymorphism and risk of PMOP and BMD {#Sec22}
------------------------------------------------

VDR *Fok*I is a polymorphism of VDR near the 50-UTR region of the gene within the DNA-binding domain, and plays an essential role in message stability and post transcriptional processes^[@CR74]^. In our meta-analysis, VDR *Fok*I was significantly associated with higher risk of developing PMOP in overall and Asian populations, but not in Caucasian populations, which is inconsistent with Zintzaras *et al*.'s meta-analysis^[@CR15]^.

Our analysis indicated that the Ff genotype of VDR *Fok*I was significantly associated with decreased BMD in the femoral neck in Caucasian populations, but not in the lumbar spine. Besides, we did not observe overall associations between VDR *Fok*I and BMD in either lumbar spine or femoral neck in either overall populations or Caucasian populations with ff genotype in our meta-analysis. A study performed by Wang *et al*.^[@CR75]^ showed that VDR *Fok*I was associated with BMD in postmenopausal Asian women, and could probably be used with other genetic markers together to identify individuals at high risk of osteoporosis. However, we could not make a certain conclusion whether VDR *Fok*I plays a key role in BMD value in Asians since no available data could be used in meta-analysis. Four studies^[@CR34],[@CR46],[@CR47],[@CR61]^ found by our searching terms were not included in Wang's study. In addition, we excluded three studies^[@CR39],[@CR60],[@CR76]^ that were recruited in Wang's study, because no sufficient data could be collected in their original articles.

VDR *Taq*I polymorphism and risk of PMOP and BMD {#Sec23}
------------------------------------------------

Unlike VDR *Bsm*I, VDR *Taq*I has been proved to affect mRNA stability, leading to altered protein levels and biological functions of Vitamin D. In our study, there was no significant association in overall and Caucasian populations, which was consistent with Zintzaras *et al*.'s study^[@CR15]^. More studies were included in our study compared with their study^[@CR15]^, suggesting that our study might provide a more precise evaluation of the relationship between VDR *Taq*I and PMOP risk. In addition, we also did not find any significant difference in lumbar spine BMD or femoral neck BMD in comparison with PNOP women with TT, Tt and tt genotypes, which is inconsistent with two studies^[@CR22],[@CR27]^. As our meta-analysis had larger sample sizes and higher statistical power, it provided a more precise evaluation of this association.

Futhermore, we should pay more attention to the implications of our results on public health and clinical practice. First, taking into consideration a significant association between VDR *Apa*I, VDR *Bsm*I, VDR *Fok*I and VDR *Taq*I and PMOP risk in different ethnicities, a conclusion might be drawn that these polymorphisms may be useful markers for osteoporosis screening in certain ethnicities. Second, screening of these genetic markers may enable an early identification of risk groups to perform preventive measures in a timely manner and also to improve treatment effectiveness, avoid complications, reduce disability and mortality rates in these patients, as well as cut down the treatment costs. Third, some more reports have confirmed the genetic background of BMD^[@CR18]^. Therefore, our results could provide theories that these VDR gene polymorphisms may be potential targets for genetic therapy of PMOP.

Our meta-analysis has some limitations that should be addressed. First, it should be remembered that in many cases it is the environmental factor that determines the development of PMOP. We should also remember that the absence of control for confounders such as smoking is one of the main limitations of our work because phenotypes of many diseases may be the results of interactions between genotyps and environmental factors. Second, no studies that explored the association between VDR *Apa*I, *Taq*I polymorphism and BMD in Asian populations, between VDR *Cdx*2 and PMOP risk in Asian populations have been found. Mendelian randomization (MR) study is a method of using measured variation in genes of known function to examine the causal effect of a modifiable exposure on disease in non-experimental studies. We had planned to perform MR study to reinforce the findings of our meta-analysis. However, convicing evidence in the literature cannot be provided to support the MR criteria.

In conclusion, VDR gene polymorphisms play keys roles in osteoporosis susceptibility and BMD in postmenopausal women, although different VDR gene polymorphisms might have significantly different influences on the risk of osteoporosis and BMD in PMOP women with various ethnicities.

Materials and Methods {#Sec24}
=====================

Literature search {#Sec25}
-----------------

Databases including PubMed, EMBASE, Web of Science, the Cochrane Library and China WeiPu Library were searched to identify case-control studies investigating the relationship between VDR gene polymorphisms and susceptibility to PMOP and BMD. The following search terms were used to find out eligible studies exploring the PMOP risk in postmenopausal women: ('PMOP' OR 'Postmenopausal osteoporosis' OR 'Postmenopausal') AND ('VDR' OR 'vitamin D receptor') AND ('polymorphism' OR 'single nucleotide polymorphism' OR 'SNP' OR 'variation'). To analyze to pooled effects of VDR gene polymorphisms on BMD in postmenopausal women, we used the following search terms to find out eligible studies: 'PMOP' OR 'Postmenopausal osteoporosis' OR 'Postmenopausal') AND ('VDR' OR 'vitamin D receptor') AND ('polymorphism' OR 'single nucleotide polymorphism' OR 'SNP' OR 'variation') AND ('BMD' OR 'bone mineral density'). Then, one-by-one screening was performed by two authors according the inclusion and exclusion criteria. No language restrictions were applied. Secondary searches of eligible studies were conducted by searching the reference lists of the selected studies, reviews or comments.

Inclusion and exclusion criteria {#Sec26}
--------------------------------

The inclusion criteria of our meta-analysis were as follows: (1) case-control studies; (2) postmenopausal women with PMOP as case populations, and postmenopausal women without PMOP or healthy women as controls; (3) studies evaluating PMOP risk, alleles and genotypes of at least one of the VDR gene polymorphisms; (3) studies providing the sample size, mean and standard deviation of BMD at lumbar spine, femoral neck or Ward's triangle in PMOP women with at least one of the VDR genotypes; (4) studies providing sufficient data (alleles and genotypes of at least one of the VDR gene polymorphisms, and BMD evaluated in cases and controls with at least one of the VDR gene polymorphisms).

The exclusion criteria were: (1) reviews or case reports that were not case-control studies; (2) studies without reporting currently available data; (3) duplicated reports.

Data extraction {#Sec27}
---------------

Data from the eligible studies were extracted according to the inclusion and exclusion criteria by two authors, and a consensus was reached by discussion if the researchers disagreed. In the study of associations between VDR gene polymorphisms and PMOP risk, the following data were collected: author list, year of publication, ethnicity, sample size, and allele and genotype of each gene polymorphism. In the analysis of difference in BMD in PMOP women with various VDR genotypes, we collected the following data: author list, year of publication, ethnicity, the number of cases, and BMD values of the femoral neck, lumbar spine or Ward's triangle in each VDR genotype in PMOP women.

Data synthesis and statistical analysis {#Sec28}
---------------------------------------

Odds ratios (OR) and 95% confidence interval (CI) were calculated to evaluate the association between VDR gene polymorphisms and PMOP. The strength of association between VDR gene polymorphisms and PMOP susceptibility was evaluated by OR and 95% CI under the allele contrast model, heterozygote model, homozygote model and dominant model. Regarding the associations between BMD and VDR gene polymorphisms, we compared BMD in PMOP women under heterozygote and homozygote models by using the weight mean difference (WMD) and 95% CI. Power analysis was performed using the Power and Precision V4 software (Biostat Inc, Englewood, USA). The heterogeneity of included studies was examined by a chi-squared-based Q statistical test and quantified by I^2^ metric value. If I^2^ value was \>50% or *P* \< 0.10, ORs were pooled by the random-effects model; otherwise, the fixed-effects model was used. Sensitivity analysis was performed to assess the impact of each study on the combined effect of the present meta-analysis, and subgroup analysis was also performed according to the ethnicity of the study populations. RevMan 5.3 software was used and a P \< 0.05 was considered as statistically significant.

Data availability {#Sec29}
-----------------

All data analyzed during this study are included in this published article (and its Supplementary Information files).
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